On April 27, 2018 Haihe Biopharma Co., Ltd. and 3D Medicines (Beijing) Co., Ltd. reported that the two sides have reached a strategic collaboration agreement on HaiHe Biopharma’s FGFR inhibitor (coded HH185) project (Press release, 3D Medicines, APR 27, 2018, View Source [SID1234594049]). 3DMed may carry out the R&D, manufacture and commercialization of HH185 in mainland China, Hong Kong, Macao and Taiwan for the treatment of cancer and pulmonary fibrosis.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Ruiping Dong, CEO of Haihe Biopharma, commented,
"As a potential target in the field of anti-tumor, FGFR is undergoing rapid development in the research of its mechanisms and clinical application and more and more verifications has been made. Therefore, the R&D prospect is so promising. As a highly selective FGFR inhibitor, HH185 overcomes the adverse effect of hepatotoxicity found in the first-generation FGFR inhibitor and has the apparent anti-tumor activity. We look forward to working together with 3DMed on the further development and commercialization of HH185, so as to accelerate the launch of the domestically-manufactured new drugs and to meet the patients’ needs in China."
Dr. Gong Zhaolong, CEO of 3D Med, commented,
"We are very happy to reach the strategic collaboration agreement with HaiHe Biopharma on HH185.HH185 has a good prospect of combination with 3DMed’s PD-L1 antibody in the field of immuno-oncology therapy. Through the collaboration with HaiHe Biopharma and by virtue of 3DMed’s platform and experience in the field of precision cancer care, we hope to be able to develop new drugs that are urgently needed in clinical practice for the benefit of even more patients who suffer from cancer and pulmonary fibrosis."
About HH185
HH185 is a small molecule inhibitor of fibroblast growth factor receptor 1,2,3 (FGFR 1,2,3), which obtained the approval for clinical trial by CNDA in January 2018. Preclinical studies have shown that HH185 has such advantages as strong anti-tumor activity, excellent PD-PK characteristics, low toxicity and high bioavailability and so on. Moreover, it is targeting CSF1-R and is therefore suitable for combination therapy with PD-1/PD-L1 antibodies in the field ofimmune-oncology.